TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

NCT07342738 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

KRAS G12V
KRAS G12D
Solid Tumor

Interventions

BIOLOGICAL: TCR-T cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Sun Yat-sen University

Collaborators

[object Object]